22838
document
Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers . INTRODUCTION Recent ex vivo platelet aggregometry data indicate that clopidogrel 75 mg/day plus acetylsalicylic acid ( ASA ) 75 mg/day is a more potent antiplatelet regimen than the marketed combination of dipyridamole+ASA . The present study was designed to assess the antithrombotic effect of both dual antiplatelet regimens using a human ex vivo model of arterial thrombosis . MATERIALS AND METHODS This was a randomized , double-blind , placebo-controlled , crossover study . During two 10-day treatment periods separated by a 14-day washout period , 23 healthy male volunteers received once-daily clopidogrel 75 mg plus acetylsalicylic acid 75 mg , or twice-daily extended-release dipyridamole 200 mg plus acetylsalicylic acid 25 mg . Assessments were made at baseline and on Day 10 of each period . Arterial thrombus formation was induced ex vivo by exposing a collagen-coated surface in a parallel-plate perfusion chamber to native blood for 3 min ( arterial wall shear rate 2600 s ( -1 ) ) . Total platelet and fibrin deposition was determined by immunoenzymatic methods . RESULTS Compared with baseline values , the mean inhibition of total platelet deposition was 63.9+/-5.9 % with clopidogrel plus acetylsalicylic acid , compared with 18.4+/-5.6 % for extended-release dipyridamole plus acetylsalicylic acid ( 67 % reduction ; 95 % CI , 49-79 % ; p < 0.0001 ) . Corresponding figures for fibrin deposition were 64.9+/-4.8 % and 18.3+/-9.7 % , respectively ( 58 % reduction ; 95 % CI , 45-67 % ; p < 0.0001 ) . Both treatments were well tolerated . CONCLUSIONS Clopidogrel plus acetylsalicylic acid showed significantly superior antithrombotic efficacy compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in humans .
22839
Intervention_Pharmacological
clopidogrel plus acetylsalicylic acid
22840
Intervention_Pharmacological
extended-release dipyridamole plus acetylsalicylic acid
22841
Intervention_Pharmacological
clopidogrel
22842
Intervention_Pharmacological
plus acetylsalicylic acid ( ASA )
22843
Intervention_Pharmacological
dipyridamole+ASA
22844
Intervention_Pharmacological
dual antiplatelet regimens
22845
Intervention_Pharmacological
clopidogrel 75 mg plus acetylsalicylic acid
22846
Intervention_Pharmacological
extended-release dipyridamole 200 mg plus acetylsalicylic acid
22847
Intervention_Pharmacological
clopidogrel
22848
Intervention_Pharmacological
acetylsalicylic acid
22849
Intervention_Pharmacological
extended-release dipyridamole
22850
Intervention_Pharmacological
acetylsalicylic acid
22851
Intervention_Pharmacological
Clopidogrel
22852
Intervention_Pharmacological
acetylsalicylic acid
22853
Intervention_Pharmacological
extended-release dipyridamole
22854
Intervention_Pharmacological
acetylsalicylic acid
22855
Outcome_Physical
Total platelet
22856
Outcome_Physical
fibrin deposition
22857
Outcome_Physical
mean inhibition of total platelet deposition
22858
Outcome_Physical
fibrin deposition
22859
Outcome_Other
tolerated
22860
Participant_Condition
healthy
22861
Participant_Sample-size
23
22862
Participant_Condition
healthy
22863
Participant_Sex
male